Not understanding variability in drug response amongst patients is currently the major limiting factor in bringing new drugs to market. Using pharmacogenomics to explain this variation and predict patient outcomes is the key to accelerated drug discovery and development, risk reduction, regulatory drug approval and product differentiation.

The 2^nd World PGx Summit has been designed by leading genomics and biomarker specialists at Pfizer, Merck, Amgen, Abbott, GSK, Johnson & Johnson, Eli Lilly, BMS, Genentech and many more to assist you in integrating and interpreting molecular profiling data to develop better drugs, quicker. From safety to efficacy, whole genome sequencing to transcriptomics, learn from industry leaders about the latest technology and methodology to explain variation in drug response and increase your drug’s chance of success. View the full speaker line up here.

What’s on the agenda?

Building on the success of last year’s meeting, we have once again designed the agenda specifically to help you make the most out of molecular data to accelerate your drug development. Learn from drug industry leaders how to integrate PGx to support your drug pipeline from lead optimization through lifecycle management and stratify patient populations. Here are just some of the topics our experts will be addressing:

• The different PGx strategies companies are taking:
  
  
  • Broad vs. targeted PGx approach
  • In-house capabilities vs. outsourcing
  • Which technologies to use?
• The practical examples of how a PGx approach has been designed and implemented with the aim of substantially improving clinical development or drug discovery (both for efficacy and/or safety) across multiple therapeutic areas
  
  
  • The regulatory requirements for PGx in drug safety assessment, genomic clinical trials and  companion diagnostic development 
  • The practical issues surrounding genomic data handling, analysis, sample collection etc.
  • When and how a predictive marker identified through PGx leads into companion diagnostic development
  • The role of high throughput omics technologies to explain variation in drug response, including whole genome sequencing

These topics will form the core of this year’s agenda. Please view the agenda pages for more details.

How is the meeting different?

The focus of this meeting is on challenges drug developers are facing in integrating molecular profiling approaches into drug development. As a result we have more senior decision makers from drug developers on the agenda than any other meeting of its kind.

If you’re a drug developer: The agenda, speakers and contacts you will make at this meeting will allow you to develop a comprehensive PGx strategy into your drug development programs. The agenda will show you how your peers are overcoming the same challenges you are facing and the world leading technology developers will be in the same room to provide solutions. 

If you’re a technology or service provider: The focus on drug developer needs is perfect. It creates the perfect environment for you to network with key decision-makers. Drug developers committed to personalized medicine who are looking for solutions. You’ll find yourself having more conversations with drug developers that lead to the prospect of business. You’ll understand the needs of your principal target market. AND learn how your competitors are addressing the same issues you're facing.

Who will attend and why?

We have a wide-range of attendees from Vice Presidents and C-Level industry leaders, to Directors, Sector Heads and Scientists across a wide range of functions including:

• Pharmacogenomics
• Genomics/genetics
• Molecular profiling
• Personalized medicine
• Translational medicine 
• Clinical research and development
• Clinical pharmacology
• Bioinformatics
• Biostatistics
• Specimen management
• Biomarkers
• Toxicogenomics
• Portfolio and project management/strategy
• Business development
• Marketing

Once a year this meeting brings together drug industry leaders and key technology providers focusing on how to use genomics and molecular profiling technologies to accelerate drug development.

Whether you are new to the field or expanding your existing capabilities around sequencing technologies and pharmacogenomics strategy, this meeting is a one-stop shop of the latest developments and strategies you need to be aware of.

Register now to speak with leaders from the world’s most forward-thinking developers and start to capitalize on the huge opportunity of pharmacogenomics to deliver better, safer drugs to market.